Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 3/20 | 0.41 |
| ▸ | ULK1 | O75385 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369787 | 0.90 | CA12 (0.51) | CA12CA1CA9CYP17A1AURKA | |
| SCHEMBL30050848 | 0.86 | CA12 (0.44) | CA12CA1CA9CYP17A1AURKA | |
| SCHEMBL2564647 | 0.86 | CA12 (0.44) | CA12CA1CA9CYP17A1AURKA | |
| SCHEMBL29781884 | 0.84 | NTRK1 (0.50) | CA12CA1CA9AURKAPSMB8 | |
| SCHEMBL4006767 | 0.83 | LRRK2 (0.53) | AURKAAURKBJAK2JAK1LRRK2 | |
| SCHEMBL18167981 | 0.82 | JAK2 (0.52) | JAK2JAK1LRRK2ITKULK1 | |
| SCHEMBL14014041 | 0.80 | ITK (0.57) | JAK2JAK1ITK | |
| SCHEMBL16052770 | 0.79 | SREBF2 (0.46) | CA12CA1CA9CYP17A1AURKA | |
| SCHEMBL30432899 | 0.78 | CA12 (0.47) | CA12CA1CA9CYP17A1AURKA | |
| SCHEMBL7368266 | 0.78 | CA12 (0.47) | CA12CA1CA9CYP17A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3083586-B1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | Bayer Pharma AG (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| WO-2015091426-A1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | CA12 4401/4885CA1 4322/4885CA9 2253/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | CA12 4431/4885CA1 4252/4885CA9 2646/4885 |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | CA12 3185/4885CA1 4461/4885CA9 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.